Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

An mHealth Trial to Promote the Use of Postpartum Contraception (PPFP)

1. august 2018 oppdatert av: Junaid-ur-Rehman Siddiqui

An mHealth, Multi-Centre Randomized Controlled Trial to Promote Use of Postpartum Contraception Amongst Rural Women in Punjab, Pakistan

Multiple encounters of pregnant women with the health care system during the late antenatal and immediate postpartum period provide a gateway for postpartum family planning counselling. Counselling on family planning services during this time is considered effective and cost-efficient for promoting healthy timing and spacing of pregnancies. This research aims to test the effectiveness of mobile phone-based interventions in promoting use of postpartum contraception.

Studieoversikt

Detaljert beskrivelse

The study will be a three-arm, 10-month, multicentre, parallel-group, randomized controlled trial which will be conducted at 15 Suraj social franchise(SF) health facilities in Punjab province of Pakistan. Pregnant women aged 15-44 years who are in their first or second trimester and have a mobile phone for their own use will be eligible to participate in this study. The participants will be randomly allocated to one of three study arms: a) voice and text messages; b) interactive telephone-based counselling; or c) control arm (no additional phone-based support). The intervention counselling module will be developed based on the Integrated Behaviour Model which was recently adapted, and tested for the family planning context in Pakistan. It will broadly cover birth-preparedness, birth spacing and contraception, and postnatal care. The phone-based intervention aims to improve women's ability to use contraception by providing them with information about a range of methods, access to family planning methods through outlets such as Suraj SF providers, connecting them with MSS field health educators to help them reach the centres, motivation by re-enforcing the benefits of contraceptive use on women's quality of life, and dispelling myths and misconceptions about modern contraceptive methods. Risk differences will be used as the measure of effect of the intervention on the outcomes.

Studietype

Intervensjonell

Registrering (Forventet)

970

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Punjab
      • Hafizabad, Punjab, Pakistan
        • Suraj Social Franchise
      • Jhang, Punjab, Pakistan
        • Suraj Social Franchise
      • Kasur, Punjab, Pakistan
        • Suraj Social Franchise
      • Toba Tek Singh, Punjab, Pakistan
        • Suraj Social Franchise

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

15 år til 44 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Married
  • Pregnant women with gestational age up to 20 weeks
  • 15-44 years old throughout duration of study
  • Literate
  • Access to a cellphone
  • Living in the study's catchment area

Exclusion Criteria:

  • Not up to 20 weeks pregnant
  • Not between 15-44 years old for the study duration
  • Illiterate
  • Does not have regular access to a cellphone
  • Not residing within the catchment area
  • Does not provide consent to participate

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Text and Voice Messages
Participants will receive text messages and voice messages
Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
Eksperimentell: Interactive Phone Call
Participants will receive interactive phone calls
Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
Ingen inngripen: Control
Participants in this arm will not be exposed to any intervention.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postpartum Contraceptive Uptake
Tidsramme: Through study completion, an average of six months
Proportion of subjects enrolled in each of the three groups who adopt any modern family planning method to delay next pregnancy
Through study completion, an average of six months
Skilled Birth
Tidsramme: Through study completion, an average of six months
Proportion of women who gave birth in a health facility or through a skilled birth professional
Through study completion, an average of six months
Immunisation
Tidsramme: Through study completion, an average of six months
Proportion of women reported to immunise the newborn at birth
Through study completion, an average of six months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Intention to Adopt Modern Contraception
Tidsramme: Through study completion, an average of six months
The proportion of subjects enrolled in the program who state that they intend to adopt any modern family planning method to delay their next birth by 24 months (by type contraceptive method and time within 42 days of postpartum period)
Through study completion, an average of six months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Xaher Gul, DrPH(c), Marie Stopes Society
  • Hovedetterforsker: Waqas Hameed, MSc, Marie Stopes Society
  • Hovedetterforsker: Junaid-ur-Rehman Siddiqui, BBA, Marie Stopes Society
  • Hovedetterforsker: Sharmeen Hussain, MPH, Marie Stopes Society
  • Hovedetterforsker: Ishaque Sheikh, MSc, Marie Stopes Society

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Forventet)

15. september 2018

Primær fullføring (Forventet)

1. august 2019

Studiet fullført (Forventet)

1. august 2019

Datoer for studieregistrering

Først innsendt

27. juli 2018

Først innsendt som oppfylte QC-kriteriene

1. august 2018

Først lagt ut (Faktiske)

2. august 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. august 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. august 2018

Sist bekreftet

1. august 2018

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 009-17

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

IPD will only be shared for underlying results in a publication. Furthermore, de-identified participant data pertinent only to the research paper will be shared.

IPD-delingstidsramme

Publication

Tilgangskriterier for IPD-deling

At the time of publication, data will be submitted to a data repository and the URL will be shared with the journal, and the journal will make the information public. Requests to access data will be individually reviewed by the research team.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere